Cargando…
Assessing immunogenicity barriers of the HIV-1 envelope trimer
Understanding the balance between epitope shielding and accessibility on HIV-1 envelope (Env) trimers is essential to guide immunogen selection for broadly neutralizing antibody (bnAb) based vaccines. To investigate the antigenic space of Env immunogens, we created a strategy based on synthetic, hig...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542815/ https://www.ncbi.nlm.nih.gov/pubmed/37777519 http://dx.doi.org/10.1038/s41541-023-00746-3 |
_version_ | 1785114174134681600 |
---|---|
author | Maliqi, Liridona Friedrich, Nikolas Glögl, Matthias Schmutz, Stefan Schmidt, Daniel Rusert, Peter Schanz, Merle Zaheri, Maryam Pasin, Chloé Niklaus, Cyrille Foulkes, Caio Reinberg, Thomas Dreier, Birgit Abela, Irene Peterhoff, David Hauser, Alexandra Kouyos, Roger D. Günthard, Huldrych F. van Gils, Marit J. Sanders, Rogier W. Wagner, Ralf Plückthun, Andreas Trkola, Alexandra |
author_facet | Maliqi, Liridona Friedrich, Nikolas Glögl, Matthias Schmutz, Stefan Schmidt, Daniel Rusert, Peter Schanz, Merle Zaheri, Maryam Pasin, Chloé Niklaus, Cyrille Foulkes, Caio Reinberg, Thomas Dreier, Birgit Abela, Irene Peterhoff, David Hauser, Alexandra Kouyos, Roger D. Günthard, Huldrych F. van Gils, Marit J. Sanders, Rogier W. Wagner, Ralf Plückthun, Andreas Trkola, Alexandra |
author_sort | Maliqi, Liridona |
collection | PubMed |
description | Understanding the balance between epitope shielding and accessibility on HIV-1 envelope (Env) trimers is essential to guide immunogen selection for broadly neutralizing antibody (bnAb) based vaccines. To investigate the antigenic space of Env immunogens, we created a strategy based on synthetic, high diversity, Designed Ankyrin Repeat Protein (DARPin) libraries. We show that DARPin Antigenicity Analysis (DANA), a purely in vitro screening tool, has the capability to extrapolate relevant information of antigenic properties of Env immunogens. DANA screens of stabilized, soluble Env trimers revealed that stronger trimer stabilization led to the selection of highly mutated DARPins with length variations and framework mutations mirroring observations made for bnAbs. By mimicking heterotypic prime-boost immunization regimens, DANA may be used to select immunogen combinations that favor the selection of trimer-reactive binders. This positions DANA as a versatile strategy for distilling fundamental antigenic features of immunogens, complementary to preclinical immunogenicity testing. |
format | Online Article Text |
id | pubmed-10542815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-105428152023-10-03 Assessing immunogenicity barriers of the HIV-1 envelope trimer Maliqi, Liridona Friedrich, Nikolas Glögl, Matthias Schmutz, Stefan Schmidt, Daniel Rusert, Peter Schanz, Merle Zaheri, Maryam Pasin, Chloé Niklaus, Cyrille Foulkes, Caio Reinberg, Thomas Dreier, Birgit Abela, Irene Peterhoff, David Hauser, Alexandra Kouyos, Roger D. Günthard, Huldrych F. van Gils, Marit J. Sanders, Rogier W. Wagner, Ralf Plückthun, Andreas Trkola, Alexandra NPJ Vaccines Article Understanding the balance between epitope shielding and accessibility on HIV-1 envelope (Env) trimers is essential to guide immunogen selection for broadly neutralizing antibody (bnAb) based vaccines. To investigate the antigenic space of Env immunogens, we created a strategy based on synthetic, high diversity, Designed Ankyrin Repeat Protein (DARPin) libraries. We show that DARPin Antigenicity Analysis (DANA), a purely in vitro screening tool, has the capability to extrapolate relevant information of antigenic properties of Env immunogens. DANA screens of stabilized, soluble Env trimers revealed that stronger trimer stabilization led to the selection of highly mutated DARPins with length variations and framework mutations mirroring observations made for bnAbs. By mimicking heterotypic prime-boost immunization regimens, DANA may be used to select immunogen combinations that favor the selection of trimer-reactive binders. This positions DANA as a versatile strategy for distilling fundamental antigenic features of immunogens, complementary to preclinical immunogenicity testing. Nature Publishing Group UK 2023-09-30 /pmc/articles/PMC10542815/ /pubmed/37777519 http://dx.doi.org/10.1038/s41541-023-00746-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Maliqi, Liridona Friedrich, Nikolas Glögl, Matthias Schmutz, Stefan Schmidt, Daniel Rusert, Peter Schanz, Merle Zaheri, Maryam Pasin, Chloé Niklaus, Cyrille Foulkes, Caio Reinberg, Thomas Dreier, Birgit Abela, Irene Peterhoff, David Hauser, Alexandra Kouyos, Roger D. Günthard, Huldrych F. van Gils, Marit J. Sanders, Rogier W. Wagner, Ralf Plückthun, Andreas Trkola, Alexandra Assessing immunogenicity barriers of the HIV-1 envelope trimer |
title | Assessing immunogenicity barriers of the HIV-1 envelope trimer |
title_full | Assessing immunogenicity barriers of the HIV-1 envelope trimer |
title_fullStr | Assessing immunogenicity barriers of the HIV-1 envelope trimer |
title_full_unstemmed | Assessing immunogenicity barriers of the HIV-1 envelope trimer |
title_short | Assessing immunogenicity barriers of the HIV-1 envelope trimer |
title_sort | assessing immunogenicity barriers of the hiv-1 envelope trimer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542815/ https://www.ncbi.nlm.nih.gov/pubmed/37777519 http://dx.doi.org/10.1038/s41541-023-00746-3 |
work_keys_str_mv | AT maliqiliridona assessingimmunogenicitybarriersofthehiv1envelopetrimer AT friedrichnikolas assessingimmunogenicitybarriersofthehiv1envelopetrimer AT gloglmatthias assessingimmunogenicitybarriersofthehiv1envelopetrimer AT schmutzstefan assessingimmunogenicitybarriersofthehiv1envelopetrimer AT schmidtdaniel assessingimmunogenicitybarriersofthehiv1envelopetrimer AT rusertpeter assessingimmunogenicitybarriersofthehiv1envelopetrimer AT schanzmerle assessingimmunogenicitybarriersofthehiv1envelopetrimer AT zaherimaryam assessingimmunogenicitybarriersofthehiv1envelopetrimer AT pasinchloe assessingimmunogenicitybarriersofthehiv1envelopetrimer AT niklauscyrille assessingimmunogenicitybarriersofthehiv1envelopetrimer AT foulkescaio assessingimmunogenicitybarriersofthehiv1envelopetrimer AT reinbergthomas assessingimmunogenicitybarriersofthehiv1envelopetrimer AT dreierbirgit assessingimmunogenicitybarriersofthehiv1envelopetrimer AT abelairene assessingimmunogenicitybarriersofthehiv1envelopetrimer AT peterhoffdavid assessingimmunogenicitybarriersofthehiv1envelopetrimer AT hauseralexandra assessingimmunogenicitybarriersofthehiv1envelopetrimer AT kouyosrogerd assessingimmunogenicitybarriersofthehiv1envelopetrimer AT gunthardhuldrychf assessingimmunogenicitybarriersofthehiv1envelopetrimer AT vangilsmaritj assessingimmunogenicitybarriersofthehiv1envelopetrimer AT sandersrogierw assessingimmunogenicitybarriersofthehiv1envelopetrimer AT wagnerralf assessingimmunogenicitybarriersofthehiv1envelopetrimer AT pluckthunandreas assessingimmunogenicitybarriersofthehiv1envelopetrimer AT trkolaalexandra assessingimmunogenicitybarriersofthehiv1envelopetrimer |